Healthcare company Baxter International (NYSE:BAX) will be reporting earnings tomorrow morning. Here’s what investors should know.
Baxter missed analysts’ revenue expectations by 29.8% last quarter, reporting revenues of $2.70 billion, up 3.8% year on year. It was a softer quarter for the company, with a significant miss of analysts’ EPS estimates.
Is Baxter a buy or sell going into earnings? Read our full analysis here, it’s free.
This quarter, analysts are expecting Baxter’s revenue to decline 2.4% year on year to $2.66 billion, improving from the 27.1% decrease it recorded in the same quarter last year. Adjusted earnings are expected to come in at $0.52 per share.
Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings.
Looking at Baxter’s peers in the medical devices & supplies - diversified segment, some have already reported their Q4 results, giving us a hint as to what we can expect. Boston Scientific delivered year-on-year revenue growth of 22.4%, beating analysts’ expectations by 3.3%, and Stryker reported revenues up 10.7%, topping estimates by 1.4%. Boston Scientific traded up 1.5% following the results while Stryker was down 1%.
Read our full analysis of Boston Scientific’s results here and Stryker’s results here.
Investors in the medical devices & supplies - diversified segment have had fairly steady hands going into earnings, with share prices down 2% on average over the last month. Baxter’s stock price was unchanged during the same time and is heading into earnings with an average analyst price target of $39.58 (compared to the current share price of $31.20).
When a company has more cash than it knows what to do with, buying back its own shares can make a lot of sense–as long as the price is right. Luckily, we’ve found one, a low-priced stock that is gushing free cash flow AND buying back shares. Click here to claim your Special Free Report on a fallen angel growth story that is already recovering from a setback.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.